Needham Assigns a Buy Rating on Stoke Therapeutics (STOK)
Needham analyst Joseph Stringer assigned a Buy rating to Stoke Therapeutics (STOK) today and set a price target of $65.00. The company’s shares closed last Tuesday at $51.82.
According to TipRanks.com, Stringer is a 1-star analyst with an average return of 0.2% and a 33.3% success rate. Stringer covers the Healthcare sector, focusing on stocks such as Apellis Pharmaceuticals, Crispr Therapeutics AG, and ACADIA Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Stoke Therapeutics with a $67.75 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $71.58 and a one-year low of $15.82. Currently, Stoke Therapeutics has an average volume of 153.3K.
Based on the recent corporate insider activity of 31 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of STOK in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Stoke Therapeutics, Inc. engages in the research and development of treatments for genetic diseases. It is a biotechnology firm that focuses to increase gene expression to treat severe genetic diseases, including genetic conditions affecting the central nervous system, eye, ear, kidney, and liver. The company was founded by Isabel Aznarez and Adrian R. Krainer in June 2014 and is headquartered in Bedford, MA.